氯沙坦钾_MSDS_用途_密度_氯沙坦钾CAS号【124750-99-8】

Losartan potassium是血管紧张素II受体1型 (AT1)拮抗剂,与血管紧张素II与AT1的结合竞争,IC50为20 nM。

点击显示

[ 描述 ]:

Losartan potassium是血管紧张素II受体1型 (AT1)拮抗剂,与血管紧张素II与AT1的结合竞争,IC50为20 nM。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 血管紧张素受体

研究领域 >> 心血管疾病

[ 靶点 ]

IC50: 20 nM (angiotensin II)

[体外研究]

氯沙坦与血管紧张素II与AT1受体的结合竞争。抑制50％血管紧张素II结合的浓度(IC50)为20 nM [1]。氯沙坦(40μM)影响ISC,但阻止ANGII对ISC的影响[2]。氯沙坦显着降低Ang II介导的子宫内膜癌细胞的增殖。与单独使用每种药物相比,氯沙坦和抗miR-155的组合具有显着更高的抗增殖作用[3]。

[体内研究]

与安慰剂治疗的Fbn1C1039G/+动物相比,氯沙坦(0.6g/L,po)处理的Fbn1C1039G/+小鼠显示远端空气口径减少。滴定氯沙坦和普萘洛尔的剂量以达到相当的血液动力学效果。对pSmad2核染色的分析显示氯沙坦拮抗Fbn1C1039G/+小鼠的主动脉壁中的TGF-β信号传导。氯沙坦可以改善肺部的疾病表现,这一事件与改善血液动力学无关[4]。氯沙坦(10 mg/kg,动脉内注射)使血液中的血管紧张素水平增加4到6倍。氯沙坦(10 mg/kg,ip)使血浆肾素水平增加100倍;血浆血管紧张素原水平降低至对照的24％;和血浆醛固酮水平没有变化[5]。

[细胞实验]

MTT测定用于测量细胞增殖和活力。对于测定，将每孔200μL培养基中的5000个细胞接种在96孔板中。在孵育过夜以允许细胞附着后，通过抽吸除去培养基。加入无血清培养基中1mg / mL浓度的MTT，然后在37℃下孵育4小时。除去MTT溶液后，加入100μLDMSO以溶解甲crystals晶体。然后使用酶标仪测量570nm处和600nm处的吸光度作为参考。因此，吸光度的差异与细胞存活的程度有关。

[动物实验]

雌性Fbn1C1039G / +小鼠与野生型雄性小鼠进行定时交配。在交配后14.5d，怀孕的雌性Fbn1C1039G / +小鼠用口服氯沙坦（饮用水中0.6g / L; n = 10），普萘洛尔（0.5g / L; n = 6）或安慰剂（n = 12）治疗。。在整个哺乳期和断奶后持续治疗至10个月大。使用上述技术处死小鼠并检查。普萘洛尔用于与氯沙坦进行比较，因为β-肾上腺素能受体阻断是目前虽然有争议的调节标准，用于调节MFS中主动脉根的异常生长。从7周龄开始，野生型和Fbn1C1039G / +小鼠用口服氯沙坦（饮用水中0.6 g / L; n = 5），普萘洛尔（0.5 g / L; n = 7）或安慰剂（n = 10）。小鼠继续口服治疗6个月，然后处死。

[参考文献]

[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.

[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.

[3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31.

[4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21.

[5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40.

[相关活性小分子]

[ 密度 ]:
0.986 g/mL at 25 °C(lit.)

[ 沸点 ]:
134 °C(lit.)

[ 熔点 ]:
−69 °C(lit.)

[ 分子式 ]:
C₂₂H₂₂ClKN₆O

[ 分子量 ]:
461.001

[ 闪点 ]:
76 °F

[ 精确质量 ]:
460.118073

[ PSA ]:
89.61000

[ LogP ]:
3.89590

[ 外观性状 ]:
白色至灰白色结晶粉末

[ 蒸汽压 ]:
1.55E-19mmHg at 25°C

[ 折射率 ]:
n20/D 1.387(lit.)

[ 储存条件 ]:
Desiccate at RT

详细MSDS(安全技术说明书)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: NI6755100

CHEMICAL NAME :: 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'-bi phenyl)-4-yl) methyl)-, monopotassium salt

CAS REGISTRY NUMBER :: 124750-99-8

LAST UPDATED :: 199701

DATA ITEMS CITED :: 11

MOLECULAR FORMULA :: C22-H23-Cl-N6-O.K

MOLECULAR WEIGHT :: 462.06

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3959,1994

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - dehydration

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3959,1994

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - altered sleep time (including change in righting reflex) Behavioral - ataxia

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3959,1994

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Lungs, Thorax, or Respiration - respiratory depression Nutritional and Gross Metabolic - dehydration

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3959,1994

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >320 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3959,1994 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 16695 mg/kg/53W-I

TOXIC EFFECTS :: Behavioral - food intake (animal) Gastrointestinal - changes in structure or function of salivary glands Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,4001,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 2450 mg/kg/14W-I

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - nausea or vomiting

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 28,3969,1994 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 763 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical

REFERENCE :: TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 51,367,1995

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2943 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception lactating female 20 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral

REFERENCE :: TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 51,367,1995

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2943 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception lactating female 20 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Specific Developmental Abnormalities - urogenital system

REFERENCE :: TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 51,367,1995

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 9265 mg/kg

SEX/DURATION :: female 15 day(s) pre-mating female 0-19 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 51,383,1995

点击显示

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xi: Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
26-36/37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
NI6755100

[ 海关编码 ]:
2933290090

详细合成路线

氯沙坦钾上游产品

氯沙坦钾下游产品

1. 戊脒盐酸盐的制备

在反应瓶中加入戊腈30g(0.361mol)和无水甲醇12g(0.375mol),搅拌溶解,在冰盐浴冷却下,通入干燥的HCl气体至增加质量18g,加盖瓶塞,侧瓶颈接无水CaCl2干燥管,放置5天,得白色结晶亚氨酯.将亚氨酯用无水甲醇溶解,加入用氨饱和的无水甲醇溶液(NH4浓度不低于9%),室温搅拌6h.抽滤,滤饼为生成的NH4Cl,弃去,滤液蒸除溶剂后得戊脒盐酸盐15g,收率30.4%(从戊腈计两步收率).该品冷却时结晶#常温时融化.戊脒盐酸盐冷却时结晶成苦味酸盐,在乙酸乙酯中重结晶#得黄色针状结晶,mp192~193ºC.

2. 2-丁基-5-羟甲基咪唑的制备

在反应瓶中加入戊脒盐酸盐5.2g(38mmol)和无水甲醇25ml,搅拌下通入NH3,使其反应液增重6g,加入二羟丙酮3.8g(42mmol)的无水甲醇20ml溶液.将其加进高压釜,室温搅拌1h.升温至40ºC,在该温度搅拌45min,升温至70ºC,在70ºC搅拌反应6h.冷却,减压蒸除溶剂,剩余物中加入适量乙腈,加热至沸,然后倾倒出乙腈溶液,重复操作几次,将残留的氯化铵弃去,合并乙腈溶液,浓缩至干,剩余物用乙酸乙酯溶解后,用硅胶柱色谱纯化,乙酸乙酯洗脱,目的物组分流出液经浓缩后,得黄色油状物,用乙酸乙酯/石油醚(bp60~90ºC)结晶,得2-丁基-5-羟甲基咪唑3.8g,为浅黄色固体,mp86~88 ºC,收率70%.

3. 2-丁基-4-氯-5-羟甲基咪唑的制备

在反应瓶中加入2-丁基-5-羟甲基咪唑1g(7mmol)、无水THF10ml,搅拌溶解#再加入N-氯代丁二酰亚胺(NCS)1g(7mmol),在40 ºC搅拌反应1h.蒸除溶剂#加入乙酸乙酯和水混合液(1:1,质量比),充分振摇,静置分层,分出乙酸乙酯层,无水NaSO4干燥,过滤,滤液减压蒸除溶剂,剩余物用石油醚(bp60~90)研磨,得白色固体2-丁基-4-氯-5-羟甲基咪唑0.7g,收率57%,mp138~140 ºC.

4. 2-丁基-4-氯-5-甲酰基咪唑的制备

在反应瓶中加入2-丁基-4-氯-5-羟甲基咪唑50g(265mmol)和冰乙酸150ml,搅拌溶解,于25º搅拌滴加1mol/L硝酸铈铵水溶液595ml(595mmol),滴加时控制反应液温度25~30ºC,滴毕,在25ºC搅拌反应3h.将反应混合物冷至0ºC,加入50%NaOH水溶液210ml,产生沉淀,调至Ph6,静置后过滤,干燥得2-丁基-4-氯-5-甲酰基咪唑38.1g,收率77%,mp92.5~93.5ºC.

5. 4,4-二甲基-2-(2-甲氧基苯基)恶唑啉的制备

在反应瓶中加入2-甲氧基苯甲酸(按文献[8~10]的方法制备)30g(0.20mol)和氯化亚砜50ml(81.9g,0.69mol),在20ºC搅拌反应18h.在真空下蒸除过量的氯化亚砜,粗品2-甲氧基苯甲酰氯,其真空蒸馏,集81~83ºC/93.33Pa馏分,2-甲氧基苯甲酰氯32g,收率95%,为无色液体,于下步反应.

在反应瓶中加入2-氨基-2-甲基-1-丙醇20g(0.224mol)和二氯甲烷100ml,搅拌下冷至0 ºC,滴加2-甲氧基苯甲酰氯17g(0.100mol)溶于二氯甲烷50ml的溶液,滴毕,升至20ºC搅拌反应2h.减压蒸除溶剂,剩余物加水稀释,析出固体,过滤,滤饼用水洗,干燥,得白色固体20.5g,该产品为粗制酰胺中间体.

在反应瓶加入上述酰胺中间体20.5g(0.092mol)和氯化亚砜22ml(36g,0.302mol),于25ºC搅拌反应1h.将反应液倒入乙醚中,析出的固体过滤收集,用乙醚洗涤,干燥.然后将其溶于水中,用1mol/LNaOH水溶液调至pH10, 用乙醚提取数次,合并有机相,无水Na2SO4干燥,过滤,滤液真空下浓缩,得4,4-二甲基-2-(2-甲氧基苯基)恶唑啉18.0g,收率88%[从2-甲氧基苯甲酰氯计]mp70~72ºC].

6. 4,4-二甲基-2-(4’-甲基联苯-2-基)恶唑啉的制备

在无水干燥反应瓶中加入无水THF200ml和镁屑2.50g(0.103mol),在N2保护下,于20ºC搅拌下滴加4-溴甲苯13ml(0.106mol) ,滴毕,搅拌反应直至镁屑全部溶解(约1h),得对甲苯基溴化镁溶液.

在反应瓶中加入4,4-二甲基-2-(2-甲氧基苯基)恶唑啉10.0g(48.7mmol)和无水THF100ml,搅拌溶解,于20ºC滴加上述对甲苯基溴化镁溶液,加毕,在20ºC搅拌反应2h.将反应混合物倒入饱和的NH4Cl水溶液中,形成的乳浊液用乙酸乙酯提取,有机相用无水Na2SO4干燥,过滤,滤液减压浓缩,得油状物粗品,经硅胶柱色谱纯化,用35%的乙酸乙酯/己烷洗脱,经后处理得4,4-二甲基-2-(4’-甲基联苯-2-基)恶唑啉11.8g,收率91%,为无色液体.

7. 2-氰基-4’-甲基联苯的制备

在反应瓶中加入4,4-二甲基-2-(4’-甲基联苯-2-基)恶唑啉243.2g(0.917mol)和吡啶975ml,于10ºC搅拌下滴入POCl3 172ml(1.84mol),在滴加过程中控制内温不超过15ºC.滴毕,升温至100ºC,在该温度搅拌反应3h.冷至室温,加水终止反应,得到的乳浊液用乙酸乙酯提取,有机相合并,用水洗,用10%CuSO4水溶液洗和用饱和食盐水洗,无水MgSO4干燥,过滤,滤液减压浓缩,剩余物用庚烷重结晶,得无色针状结晶2-氰基-4’-甲基联苯169.6g,收率96%,mp48.0~49.5ºC.

8. N-(三苯基甲基)-5-(4’-甲基联苯-2-基)-四氮唑的制备

在反应瓶中加入2-氰基-4’-甲基联苯9.0g(46.6mmol)、三丁基氯化锡16.4g(50.4mmol)、叠氮化钠30g(46.2mmol)和甲苯35ml,搅拌回流70h.加入甲苯30ml稀释,并冷至20ºC.再加入10mol/LNaOH水溶液5.5ml(55mmol)和三苯基氯甲烷13.5g(48.4mmol),在20ºC搅拌反应3h.向反应液加入蒸馏水35ml和庚烷70ml,冷至0ºC搅拌1.5h.将浆状物过滤,固体用水洗和庚烷/甲苯(1:1)洗涤,抽干,得粗制品N-(三苯基甲基)-5-(4’-甲基联苯-2-基)-四氮唑,将其溶于二氯甲烷,然后依次用0.4mol/L NaOH水溶液、水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,滤液减压浓缩,得N-(三苯基甲基)-5-(4’-甲基联苯-2-基)-四氮唑15.1g,收率68%,mp163~166ºC.

9. N-(三苯基甲基)-5-[4’-(溴甲基)联苯-2-基]-四氮唑的制备

在反应瓶中加入N-(三苯基甲基)-5-(4’-甲基联苯-2-基)-四氮唑31.0g(65mmol)、N-溴代丁二酰亚胺(NBS)11.50g(65mmol)和四氯化碳390ml,搅拌回流3h.冷至40ºC,过滤,滤液真空浓缩回收溶剂,得到N-(三苯基甲基)-5-[4’-(溴甲基)联苯-2-基]-四氮唑粗品,粗品不需进一步纯化,可用于下步反应.将粗品加入二异丙醚捣碎研磨,得到N-(三苯基甲基)-5-[4’-(溴甲基)联苯-2-基]-四氮唑纯品33.10g,收率92%,为类白色固体,mp135~138 ºC.

10. 2-丁基-4-氯-5-甲酰基-1-[[[2’-(三苯甲基)四氮唑-5-基]联苯-4-基]甲基]咪唑的制备

在反应瓶中加入2-丁基-4-氯-5-甲酰基咪唑3.27g(17.5mmol)、N-(三苯基甲基)-5-[4’-(溴甲基)联苯-2-基]-四氮唑10.73g(19.3mmol)、K2CO3 4.83g(35mmol)和DMF100ml,在25 ºC搅拌反应24h.过滤,滤液减压浓缩,

剩余物加水稀释,用乙酸乙酯提取,合并有机相,用水洗)饱和盐水洗,无水MgSO4干燥,过滤,滤液浓缩,浓缩液经硅胶柱色谱纯化,用乙酸乙酯/甲苯洗脱,经后处理得2-丁基-4-氯-5-甲酰基-1-[[[2’-(三苯甲基)四氮唑-5-基]联苯-4-基]甲基]咪唑5.69g,收率49%.

11. 2-丁基-4-氯-5-(羟甲基)-1-[[2’-(三苯甲基)四氮唑-5-基]联苯-4-基]甲基]咪唑的制备

在反应瓶中加入2-丁基-4-氯-5-甲酰基咪唑3.57g(21mmol)、四丁基溴化磷0.71g(21mmol)、10mol/LNaOH水溶液4.2ml(42mmol)、水15ml和二氯甲烷70ml,搅拌下加入N-(三苯基甲基)-5-[4’-(溴甲基)联苯-2-基]-四氮唑11.65g(21mmol)溶于二氯甲烷100ml的溶液,于25ºC搅拌反应24h.向反应混合物加入硼氢化钠(NaBH4)0.79g(21mmol),再继续搅拌反应24h.加水200ml,静置分层,分出有机相,用水(200ml×2)洗,无水MgSO4干燥,过滤,滤液减压蒸除溶剂,得黄色玻璃状固体2-丁基-4-氯-5-(羟甲基)-1-[[2’-(三苯甲基)四氮唑-5-基]联苯-4-基]甲基]咪唑13.3g,用硝基甲烷重结晶,得2-丁基-4-氯-5-(羟甲基)-1-[[2’-(三苯甲基)四氮唑-5-基]联苯-4-基]甲基]咪唑精品类白色粉末7.52g,收率54%,mp167~169ºC.

12. 氯沙坦钾的合成

在反应瓶中加入化合物2-丁基-4-氯-5-(羟甲基)-1-[[2’-(三苯甲基)四氮唑-5-基]联苯-4-基]甲基]咪唑9.20g(13.8mmol)、10%盐酸100ml和THF200ml,于25ºC搅拌反应4h.加入过量的10%NaOH水溶液(约100ml)减压蒸除溶剂,剩余物用水溶解,过滤除去副产物三苯甲醇,滤液用盐酸调至Ph3,析出沉淀,过滤收集沉淀,得氯沙坦粗制品,重结晶后得氯沙坦氯沙坦钾5.18g,收率89%,mp183.5~184.5ºC.

点击显示

[ 海关编码 ]: 2933290090

[ 中文概述 ]:
2933290090. 其他结构含非稠合咪唑环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synthesis and evaluation of the novel 2-[¹⁸F]fluoro-3-propoxy-triazole-pyridine-substituted losartan for imaging AT₁ receptors.

Bioorg. Med. Chem. 22(15) , 3931-7, (2014)

The 2-[(18)F]fluoro-3-pent-4-yn-1-yloxypyridine ([(18)F]FPyKYNE) analog of the potent non-peptide angiotensin II type 1 receptor (AT1R) blocker losartan was produced via click chemistry linking [(18)F...

Role of 5-HT7 receptors in the inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats

Vascul. Pharmacol. 63(1) , 4-12, (2014)

The role of calcitonin gene-related peptide (CGRP) in the modulation of vascular tone has been widely documented. Indeed, electrical stimulation of the perivascular sensory outflow in pithed rats indu...

Simultaneous determination of polar pharmaceuticals and personal care products in biological organs and tissues.

J. Chromatogr. A. 1355 , 193-205, (2014)

In the present study, a sensitive and accurate isotope dilution method was developed for the simultaneous determination of 17 polar pharmaceutical and personal care product (PPCP) residues (logKow=1.4...

更多文献